Diebold Nixdorf (DBD) closed at $57.98 on November 4, 2026, up 3.9% from the previous close, on volume of 405,955 shares (30-day average 304,326).
Data as of November 4, 2026.
4-Nov-2026
Diebold Nixdorf (DBD) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Wed, 4-Nov 10:11 AM ET)
Diebold Nixdorf Earnings Call Shows Growth Amid Pressure
TipRanks (Mon, 2-Nov 7:16 PM ET)
Globe Newswire (Mon, 2-Nov 9:01 AM ET)
DBD Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Diebold Nixdorf (DBD)
ACCESS Newswire (Fri, 30-Oct 11:55 AM ET)
PRNewswire (Thu, 29-Oct 10:12 AM ET)
Market Chameleon (Wed, 28-Oct 4:00 AM ET)
Diebold Nixdorf Board of Directors Authorizes New $250 Million Share Repurchase Program
PRNewswire (Wed, 28-Oct 7:01 AM ET)
Diebold Nixdorf Reports Third Quarter Revenue and Adjusted EBITDA Growth
PRNewswire (Wed, 28-Oct 7:01 AM ET)
Globe Newswire (Mon, 26-Oct 4:05 PM ET)
Diebold Nixdorf Enables stc pay Bahrain to Bridge Digital and Physical Financial Services
PRNewswire (Thu, 8-Oct 8:38 AM ET)
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
Diebold Nixdorf trades on the NYSE stock market under the symbol DBD.
As of November 4, 2026, DBD stock price climbed to $57.98 with 405,955 million shares trading.
DBD has a beta of 0.58, meaning it tends to be less sensitive to market movements. DBD has a correlation of 0.02 to the broad based SPY ETF.
DBD has a market cap of $1.95 billion. This is considered a Small Cap stock.
Last quarter Diebold Nixdorf reported $994 million in Revenue and $1.34 earnings per share. This beat revenue expectation by $24 million and exceeded earnings estimates by $.03.
In the last 3 years, DBD traded as high as $92.09 and as low as $18.81.
The top ETF exchange traded funds that DBD belongs to (by Net Assets): IJR, VTI, AVUV, IWM, VXF.
DBD has underperformed the market in the last year with a price return of +3.1% while the SPY ETF gained +14.7%. DBD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.5% and -14.9%, respectively, while the SPY returned -0.3% and -0.8%, respectively.
DBD support price is $54.39 and resistance is $57.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DBD shares will trade within this expected range on the day.